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Half-lives of various molecules in joints.
Molecule Molecular weight Half-life (hours)
Acetaminophen 151 1.1
Lidocaine 234 0.4
Indomethacin 358 2.8
Cortisone; hydroxycortisone 360, 363 0.4e4.2
Evans Blue 963 0.9Asked why he robs banks, the gangster Willie Sutton famously
replied: “because that's where the money is”. The same logic can
be applied to intra-articular therapy. Why inject drugs into joints?
e Because that's where the arthritis is. But robbing banks is easier.
The main problem is that anything injected into a joint tends to
come back out again very quickly. This restricts the effectiveness of
intra-articular treatments to acute conditions, such as injuries and
ﬂares. There is a pressing need for technologies to retain drugs in
joints and thus permit sustained therapeutic responses in chronic
conditions such as osteoarthritis (OA). Furthermore, accumulating
large amounts of a therapeutic within the joint space is not very
helpful if the target cells are chondrocytes and the agent cannot
penetrate the extracellular matrix of cartilage. A paper by Bajpayee
et al.1 in this issue of Osteoarthritis and Cartilage addresses these
matters.
Thanks to the pioneering studies of Peter Simkin, University of
Washington, Seattle and Rodney Levick, St George's Medical School,
London, we have a good understanding of the pharmacokinetics of
the knee joint2. Small molecules, such as NSAIDs and glucocorti-
coids, diffuse out of the joint space very quickly via the sub-
synovial capillaries. And it is no good trying to address this by form-
ing large conjugates, because macromolecules are also rapidly
cleared, in this case via the lymphatics, in amanner that is indepen-
dent of their size. Proteins and glycosaminoglycans (GAGs), for
instance, have intra-articular half-lives of only a few hours. Larsen
et al.3 have compiled the intra-articular half-lives of various rele-
vant molecules (Table I).
Because frequent, repeated intra-articular injections are not
feasible, several alternative strategies have emerged in attempts
to solve the problem of drug retention. Gene transfer is one of
them. The idea is to introduce cDNAs into the cells of the joint so
they produce the encoded products endogenously for an extended
period of time. This technology works best when the drug is a pro-
tein or species of non-coding RNA, but it can also be used to express
enzymes catalyzing the synthesis of relevant small molecules; de-
livery of glutamine: fructose-6-phosphate amidotransferase, for
example, enhances the local synthesis of glucosamine4. Although
arthritis gene therapy shows considerable pre-clinical promise
and is being evaluated in human trials5, its route to clinical applica-
tion is long, tortuous and expensive6,7.
A popular alternative is to combine drugs with slow-release
nano- or micro-particles for intra-articular injection. The problem
here is that these particles, too, are rapidly cleared by theDOI of original article: http://dx.doi.org/10.1016/j.joca.2015.07.010.
http://dx.doi.org/10.1016/j.joca.2015.08.012
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trate cartilage. Even though nano-sized particles may do so, in
the absence of an intra-cartilage retention mechanism they will
diffuse right back out again. As things stand, the duration and
magnitude of clinical beneﬁt using particles as delivery vehicles is
only incrementally greater than that of the free drug8.
Alan Grodzinsky and his colleagues at MIT have pioneered alter-
native strategies in which drugs or drug carriers are modiﬁed to
bind to the extracellular matrix of cartilage. This approach nicely
converts the matrix from a barrier to an accomplice when deliv-
ering molecules to chondrocytes. In their ﬁrst successful demon-
stration of this approach, collaborating with Richard Lee and co-
workers of Harvard Medical School, insulin-like growth factor-1
was engineered to contain a heparin-binding domain9. In the cur-
rent issue of Osteoarthritis and Cartilage, Bajpayee et al.1 report a
reﬁnement of this tactic using avidin as the anchor.
Avidin has several unique advantages in the present context.
With a diameter of about 7 nm, it is small enough to diffuse into
intact cartilage, whose cut-off has been estimated at around
10 nm. It is highly cationic, leading to Donnan (electrostatic) interac-
tions that generate at least a six-fold upward partitioning factor at
the synovial ﬂuidecartilage interface. This increases the intra-
tissue concentration gradient, signiﬁcantly enhancing avidin's trans-
port and uptake inside the cartilage. Moreover, its favorable net pos-
itive charge enables weak and reversible ionic binding with GAGs
(KD ~ 150 mM) allowing avidin to diffuse throughout the whole
depth of the cartilage. Despite weak binding, it has long intra-
tissue residence time because of the extremely high binding site
density of the negatively charged groups (NT ~ 3000 mM)10. This en-
sures that cartilage not only accumulates considerable amounts of
avidin throughout its entire thickness but also releases it internally
(see Fig. 1). If avidin is conjugated to a drug, the latter then becomes
available to chondrocytes. Avidin's effectiveness as a delivery vehicle
to cartilage has been conﬁrmed in vivo in rats and rabbits11,12.Albumin 6.7  104 1e13
Hyaluronan 0.1/ 6  106 10e26
Aggrecan 2.5  106 12.5
From Larsen et al., reference 3.
td. All rights reserved.
Fig. 1. (A) Intra-articular injection of positively charged avidin-drug conjugates enables rapid penetration and uptake into the deep zones of cartilage due to electrostatic interac-
tions. This creates an intra-tissue depot of the drug. (B) Micron sized particles, however, cannot penetrate cartilage. In absence of an active binding agent, these particles, as well as
drugs they may release, can be cleared rapidly from the joint space.
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gate. Dexamethasone was selected following our discovery that it
dramatically protects cartilage from the combined effects of inju-
rious compression and inﬂammatory cytokines without compro-
mising matrix synthesis or other aspects of chondrocyte
metabolism13. This ﬁnding has resulted in a clinical trial to evaluate
the possibility that a single, intra-articular injection of dexametha-
sone after injury to the joint can prevent the onset of post-
traumatic OA14. The intra-articular transience of dexamethasone
is, however, a concern.
Bajpayee et al.1 covalently attached dexamethasone to avidin us-
ing ester or pH-sensitive hydrazone linkers, designed to release
dexamethasone quickly (t1/2 ~ 14 h) or slowly (t1/2 ~ 57 h in an
acidic environment), respectively. Looking ahead to possible clin-
ical application, a PEGylated version of avidin was also synthesized
to reduce immunogenicity. The potency of these molecules was
determined in an in vitro assay systemwhere disks of bovine artic-
ular cartilage were exposed to interleukin-1. This resulted in deple-
tion of proteoglycan from the matrix, inhibition of GAG synthesis
and cell death. Avidin-delivered dexamethasone protected against
each of these responses. A single application of unconjugated dexa-
methasone was less effective than a similar single application of an
avidin-dexamethasone conjugate, with a 1:1 mix of the slow and
fast releasing formulations being the most potent. No cytotoxicity
was observed.
These promising data have motivated evaluation of new conju-
gates in animal models of joint disease, which may lead to clinical
trials in human and veterinary medicine. Novel approaches such as
these have much to offer in the continuing quest to develop
disease-modifying drugs for OA.
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